Substances and methods for the use in prevention and/or treatment in huntington's disease
AssigneeHd Immune GmbH
InventorsOskar SMRZKA, Stefan BARTL, Michela PARTH
Life of this patent
Estimating the term…
Abstract
Disclosed is an apheresis device including a solid carrier capable of being contacted with the blood or plasma flow, characterised in that the solid carrier includes one or several HTT-binding molecule(s) capable of adsorbing HTT or fragments thereof in a specific manner from plasma or blood or other HTT containing body fluids such as CSF.
Claims16
An anti-Huntingtin (HTT) protein monoclonal antibody, having a binding domain that binds to a peptide of the HTT protein having the sequence of p6773 (SEQ ID NO:
- 1).
A monoclonal antibody having a binding domain that specifically binds to a peptide of the HTT protein having the sequence of p7543 (SEQ ID NO:
- 3).
A monoclonal antibody having a binding domain that specifically binds to a peptide of the HTT protein having the sequence of p7564 (SEQ ID NO:
- 2).
A method to monitor progression of Huntington's Disease or to monitor effectiveness of a treatment of Huntington's Disease in a subject, comprising:
- determining the level of mutated HTT or fragment thereof in a sample obtained from the subject by detection of complexes with one or more antibodies selected from the group consisting of PRR13, MID1 and C6-17;
- and
- determining the progress of Huntington's disease or the effectiveness of treatment of Huntington's disease by comparing the obtained level of mutated HTT or fragment thereof with one or more levels previously measured from a sample obtained from the subject.
An antibody or antigen-binding molecule targeting the caspase region 586 region of HTT generated by immunisation with peptide-based vaccines, comprising at least one immunogenic peptide selected from the group consisting of p7564 (CPSDSSEIVLD), p7543 (GTDNQYLGLQIGC), p8855 (SDSSEIVLDGTDC), p8858 (EIVLDGTDNQYLC), p8859 (IVLDGTDNQYLGC), p8860 (VLDGTDNQYLGLC), p8861 (LDGTDNQYLGLQC), p8862 (DGTDNQYLGLQIGC), p8869 (CTDNQYLGLQIGQ), p8868 (CGTDNQYLGLQIG), p8870 (CDNQYLGLQIGQP), p8871 (CNQYLGLQIGQPQ), p8864 (TDNQYLGLQIGQC), p8865 (DNQYLGLQIGQPC), p8854 (PSDSSEIVLDGTC), p8856 (DSSEIVLDGTDNC), p8857 (SEIVLDGTDNQYC), p8866 (NQYLGLQIGQPQC), and p8867 (QYLGLQIGQPQDC), wherein the N- or C-terminal cysteine residue (C) may be present or not or provided alternatively at the C- or N-terminus.
Dependencies are inferred from the claim text.